Xbiotech

Austin‑based XBiotech develops True Human monoclonal antibodies and IL‑1α therapies for inflammatory, infectious and cardiovascular diseases, positioning itself as a growing player in targeted immuno‑therapy.

Headquarters: United States (USA)

Xbiotech Logo
Company Profile
Traded Instruments
+ Add Instrument 1
Symbol Name Type Exchange Currency ISIN Status Actions
XBIT Xbiotech
Cap: 0.1B
EQUITY NMS USD CA98400H1029 Active
📈
Home Login